Abarca Health and LucyRx to Merge, Forming New PBM Amid Industry Consolidation

Independent pharmacy benefit managers Abarca Health and LucyRx announced on June 17, 2026, that they have agreed to merge, creating a new entity aimed at challenging the nation’s largest PBMs. The combined company will operate under a new parent organization, Healthcare Revolution Partners, and will serve more than 9 million plan members across the United States.

The deal comes as the PBM industry faces intense regulatory scrutiny and public demand for greater transparency and competition in prescription drug pricing. Pharmacy benefit managers, or PBMs, function as intermediaries between drug manufacturers, health insurers, and pharmacies to negotiate drug prices and manage prescription drug benefits for employers and health plans. The U.S. market is heavily concentrated, with about 80% controlled by three major players: CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx.

The merger between Abarca and LucyRx is positioned as a direct response to this market dynamic. In our experience, when industries consolidate, mid-sized businesses often feel the squeeze, facing fewer choices and less negotiating power. This merger could create a viable fourth option, but its success will depend heavily on a smooth operational integration, which is never guaranteed.

Under the terms of the agreement, both San Juan, Puerto Rico-based Abarca and Bethesda, Maryland-based LucyRx will retain their existing brand names and operate as wholly owned subsidiaries of Healthcare Revolution Partners. Financial details of the transaction were not disclosed. The companies stated that continuity for clients and members is a top priority, with no disruptions expected in day-to-day operations. Leadership will also remain in place, with Abarca CEO Jason Borschow and LucyRx CEO David Blair continuing in their roles while also serving as co-chairs of the new parent company. The transaction is expected to close in the third quarter of 2026, pending customary regulatory approvals.

Executives from both companies framed the merger as a necessary step to gain scale in an increasingly complex environment. “The market is at a breaking point,” said Borschow in a statement. “Clients are demanding real accountability. And the regulatory environment increasingly rewards scale and transparency.” This sentiment reflects growing pressure from federal and state lawmakers who are investigating PBMs for allegedly anticompetitive practices and their role in rising drug costs. The new entity, according to the announcement, aims to create “the only modern, independent pharmacy benefit manager with the scale, technology, and track record to credibly serve commercial and government clients of any size.”

While this deal creates a stronger competitor, the complexities of integrating two separate companies, their technology platforms, and their client contracts are substantial. For any business that relies on these PBMs, or is considering them as a new vendor, this period of transition introduces uncertainty. Our mergers and acquisitions advisory practice at C&S Finance Group LLC frequently guides clients through the due diligence required to assess the operational and financial risks associated with such corporate actions. Understanding the potential for service disruption versus the promise of greater efficiency is critical, and we help businesses make that assessment at csfinancegroup.com.

David Blair of LucyRx added that the combined company will leverage its new scale to “accelerate the healthcare revolution Abarca started more than 20 years ago.” He emphasized a commitment to delivering “total-cost-of-care savings anchored in putting patients first.” The new parent company, Healthcare Revolution Partners, is described as a “mission-led union of like-minded organizations” focused on creating a more seamless and personalized healthcare experience.

The combined Abarca-LucyRx entity will rank among the top 10 largest PBMs in the country based on the number of prescriptions managed. However, it will still be significantly smaller than the dominant three, underscoring the challenge ahead. Industry analysts suggest this merger could trigger further consolidation among the remaining smaller, independent PBMs who may find it difficult to compete with the scale and resources of larger rivals, especially as administrative burdens from new regulations increase.

The strategic focus for the two brands will remain distinct. LucyRx will continue to concentrate on its core markets of employers and third-party administrators (TPAs), while Abarca will maintain its focus on health plans and government programs. This division of labor is intended to ensure that existing client relationships and market expertise are preserved during the integration.

Industry observers will be closely watching whether Healthcare Revolution Partners can successfully integrate its two subsidiaries and deliver on its promise of a more transparent and cost-effective alternative in the PBM market. The deal's closure in the third quarter and any subsequent moves by other independent PBMs will provide key signals about the future landscape of prescription drug management.